Skip to Content
Merck
All Photos(3)

Documents

HT90132

Sigma-Aldrich

Crystal Violet Solution

Sign Into View Organizational & Contract Pricing
All Photos(3)

About This Item

Empirical Formula (Hill Notation):
C25H30ClN3
CAS Number:
548-62-9
Molecular Weight:
407.98
Beilstein:
3580948
MDL number:
MFCD00011750
UNSPSC Code:
12352200
PubChem Substance ID:
329815275
NACRES:
NA.47

form

solution

Quality Level

500

shelf life

Expiry date on the label

IVD

for in vitro diagnostic use

concentration

2.3%

pH

4.6

application(s)

hematology
histology

storage temp.

room temp

SMILES string

[Cl-].CN(C)c1ccc(cc1)\C(c2ccc(cc2)N(C)C)=C3/C=C\C(C=C3)=[N+](/C)C

InChI

1S/C25H30N3.ClH/c1-26(2)22-13-7-19(8-14-22)25(20-9-15-23(16-10-20)27(3)4)21-11-17-24(18-12-21)28(5)6;/h7-18H,1-6H3;1H/q+1;/p-1

InChI key

ZXJXZNDDNMQXFV-UHFFFAOYSA-M

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Intended for use in the Gram Stain Procedure No. HT90.

Components

Contains 2.3% certified crystal violet, 0.1% ammonium oxalate and 20% ethyl alcohol, SD3A.

Signal Word

Warning

Hazard Statements

H226 - H319 - H351 - H412

Hazard Classifications

Aquatic Chronic 3 - Carc. 2 - Eye Irrit. 2 - Flam. Liq. 3

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

100.0 °F - closed cup

Flash Point(C)

37.8 °C - closed cup

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

EU REACH Annex XVII (Restriction List)

CAS No.

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 4

1 of 4

Gram’s safranin solution for microscopy

Sigma-Aldrich

94635

Gram′s safranin solution

Gentian Violet meets USP testing specifications

Sigma-Aldrich

G2039

Gentian Violet

Gentian Violet United States Pharmacopeia (USP) Reference Standard

USP

1290002

Gentian Violet

Safranin O solution

Sigma-Aldrich

HT90432

Safranin O solution

Chia-Hsun Fang et al.
Journal of biomedical science, 27(1), 42-42 (2020-03-15)
The underlying mechanism involved in ovarian cancer stemness and chemoresistance remains largely unknown. Here, we explored whether the regulation of c-Kit and plasma membrane prohibitin (PHB) affects ovarian cancer stemness and chemotherapy resistance. Mass spectrum analysis and an in vitro
Bin Xiao et al.
Cell reports, 31(4), 107571-107571 (2020-04-30)
Mechanistic target of rapamycin complex 1 (mTORC1) is a master modulator of cellular growth, and its aberrant regulation is recurrently documented within breast cancer. While the small GTPase Rheb1 is the canonical activator of mTORC1, Rheb1-independent mechanisms of mTORC1 activation
Daniel Haensel et al.
EMBO reports, 20(1) (2018-11-11)
Directional migration is inherently important for epithelial tissue regeneration and repair, but how it is precisely controlled and coordinated with cell proliferation is unclear. Here, we report that Ovol2, a transcriptional repressor that inhibits epithelial-to-mesenchymal transition (EMT), plays a crucial
Chao Wan et al.
Science advances, 6(13), eaay9789-eaay9789 (2020-04-02)
Radiotherapy (RT) is routinely used in cancer treatment, but expansion of its clinical indications remains challenging. The mechanism underlying the radiation-induced bystander effect (RIBE) is not understood and not therapeutically exploited. We suggest that the RIBE is predominantly mediated by
Niklas Gremke et al.
Nature communications, 11(1), 4684-4684 (2020-09-19)
Cancer cells have a characteristic metabolism, mostly caused by alterations in signal transduction networks rather than mutations in metabolic enzymes. For metabolic drugs to be cancer-selective, signaling alterations need to be identified that confer a druggable vulnerability. Here, we demonstrate
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service